The CYP2A6v2 Polyclonal Antibody (PACO02535) is a valuable tool for researchers studying the cytochrome P450 2A6 variant 2 enzyme. This antibody, generated in rabbits, exhibits high reactivity with human samples and is specifically designed for use in Western blot applications. By binding to the CYP2A6v2 protein, this antibody allows for accurate detection and analysis in a variety of cell types, making it an essential component for investigations in drug metabolism, toxicology, and personalized medicine.
The cytochrome P450 2A6 variant 2 enzyme plays a crucial role in the metabolism of a wide range of xenobiotics, including drugs, carcinogens, and environmental toxins. Understanding the expression and function of this enzyme is essential for predicting individual responses to pharmacological agents and assessing potential risks of chemical exposures. The CYP2A6v2 Polyclonal Antibody offers researchers a reliable tool for gaining insights into the role of this enzyme in health and disease.
Antibody Name:
CYP2A6V2 Antibody
Antibody SKU:
PACO02535
Size:
50ug
Host Species:
Rabbit
Tested Applications:
ELISA, WB, IHC
Recommended Dilutions:
WB:1:500-1:2000, IHC:1:100-1:300
Species Reactivity:
Human
Immunogen:
synthesized peptide derived from the Internal region of human CYP2A6V2.
Form:
Liquid
Storage Buffer:
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Purification Method:
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Clonality:
Polyclonal
Isotype:
IgG
Conjugate:
Non-conjugated
Synonyms:
Cytochrome P450
UniProt Protein Function:
CYP2A6: Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4- cineole 2-exo-monooxygenase. Possesses low phenacetin O- deethylation activity. Belongs to the cytochrome P450 family.Protein type: Xenobiotic Metabolism - drug metabolism - cytochrome P450; Cofactor and Vitamin Metabolism - retinol; Oxidoreductase; Secondary Metabolites Metabolism - caffeine; Xenobiotic Metabolism - drug metabolism - other enzymes; EC 1.14.14.1; Endoplasmic reticulumChromosomal Location of Human Ortholog: 19q13.2Cellular Component: endoplasmic reticulum membrane; intracellular membrane-bound organelle; cytoplasmic microtubuleMolecular Function: coumarin 7-hydroxylase activity; enzyme binding; iron ion binding; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen; heme binding; arachidonic acid epoxygenase activity; steroid hydroxylase activity; oxygen bindingBiological Process: steroid metabolic process; coumarin metabolic process; xenobiotic metabolic process; coumarin catabolic process; exogenous drug catabolic process; epoxygenase P450 pathway; drug metabolic processDisease: Tobacco Addiction, Susceptibility To; Lung Cancer; Coumarin Resistance
UniProt Protein Details:
NCBI Summary:
This gene, CYP2A6, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by phenobarbital. The enzyme is known to hydroxylate coumarin, and also metabolizes nicotine, aflatoxin B1, nitrosamines, and some pharmaceuticals. Individuals with certain allelic variants are said to have a poor metabolizer phenotype, meaning they do not efficiently metabolize coumarin or nicotine. This gene is part of a large cluster of cytochrome P450 genes from the CYP2A, CYP2B and CYP2F subfamilies on chromosome 19q. The gene was formerly referred to as CYP2A3; however, it has been renamed CYP2A6. [provided by RefSeq]